Biomarin Pharmaceutical (BMRN) EBITDA (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly EBITDA came in at $129.6 million in Q1 2026, down 42.1% YoY from $223.9 million in Q1 2025, and up 390.61% on a QoQ basis from -$44.6 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) EBITDA (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of EBITDA data on file, last reported at $129.6 million in Q1 2026.
- Quarterly EBITDA fell 42.1% year-over-year to $129.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $315.2 million (down 49.13% YoY) and the FY2025 annual result came in at $409.5 million, down 15.43% from the prior year.
- EBITDA grew to $129.6 million in Q1 2026, from -$44.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $276.9 million in Q2 2025 to a low of -$46.7 million in Q3 2025.
- A 5-year average of $80.6 million and a median of $65.6 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA surged 1362.93% — and 2025, when it tumbled 141.0%.
- Tracing BMRN's EBITDA over 5 years: stood at -$13.1 million in 2022, then surged by 308.43% to $27.3 million in 2023, then surged by 491.69% to $161.4 million in 2024, then plunged by 127.64% to -$44.6 million in 2025, then soared by 390.61% to $129.6 million in 2026.
- The last three EBITDA figures came in at $129.6 million (Q1 2026), -$44.6 million (Q4 2025), and -$46.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 110.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.92 Mn |
| Mar 31, 2026 | 129.64 Mn |
| Dec 31, 2025 | -44.61 Mn |
| Sep 30, 2025 | -46.69 Mn |
| Jun 30, 2025 | 276.89 Mn |
| Mar 31, 2025 | 223.89 Mn |
| Dec 31, 2024 | 161.41 Mn |
| Sep 30, 2024 | 113.89 Mn |
| Jun 30, 2024 | 120.45 Mn |
| Mar 31, 2024 | 88.46 Mn |
| Dec 31, 2023 | 27.28 Mn |
| Sep 30, 2023 | 30.53 Mn |
| Jun 30, 2023 | 65.57 Mn |
| Mar 31, 2023 | 62.40 Mn |
| Dec 31, 2022 | -13.09 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | 39.15 Mn |
| Mar 31, 2022 | 137.33 Mn |
| Dec 31, 2021 | -65.88 Mn |
| Sep 30, 2021 | -53.22 Mn |